The Latest
HUTCHMED Announces NMPA Approval For ATLED® (Fanregratinib) For The Treatment Of Patients With FGFR2-Fusion/Rearrangement Intrahepatic Cholangiocarcinoma
HUTCHMED announces NMPA approval for ATLED® (Fanregratinib) to treat FGFR2-fusion intrahepatic cholangiocarcinoma, expanding options for this cancer type.